Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide.
Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma …

Clinical refractoriness to nucleoside analogs (eg, gemcitabine, capecitabine) is a major
scientific problem and is one of the main reasons underlying the extremely poor prognostic …

The current treatment of choice for metastatic pancreatic cancer involves single-agent
gemcitabine or a combination of gemcitabine with capecitabine or erlotinib (a tyrosine …

Introduction: Pancreatic cancer has the worst survival rate of all cancers. The current
standard care for metastatic pancreatic cancer is gemcitabine, however, the success of this …

Pancreatic cancer is one of the most lethal types of cancer in the world. The incidence of
pancreatic cancer increases each year with no significant decrease in mortality. Pancreatic …

Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths. The
disappointing 5-year survival rate of below 5% stems from drug resistance to all known …

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant
cancers, and current therapies targeting cancer-associated molecular pathways have not …

Introduction: Pancreatic cancer (PC) is the fourth leading cause of cancer-related deaths in
the US and Europe, and the lethality of this cancer is demonstrated by the fact that the …

Pancreatic ductal adenocarcinoma, an exocrine tumor, is the most common type of cancer of
the pancreas and one of the top five most prominent causes of cancer-associated mortality …

Most human cancers display high levels of heterogeneity, a feature that often impacts
negatively on the response to treatments. Indeed, while radio and/or chemotherapy initially …